Adaptive Phage Therapeutics Initiates Phase 1/2 Trial of PhageBank™ in Urinary Tract Infections

Published on : Published by : BioBuzz Media

Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the first patient has been dosed in a Phase 1/2 study of bacteriophage therapy (PhageBank™) to evaluate the safety, tolerability, and efficacy of targeted, personalized, bacteriophage (“phage”) treatments in patients with urinary tract infection (UTI).

Global Biotech Company, Ellume, to Open Manufacturing Facility in Frederick

Published on : Published by : BioBuzz Media

Governor Larry Hogan today announced that Ellume, an Australia-based digital diagnostics company, will establish its first U.S. manufacturing operation in Frederick County and create more than 1,500 new jobs by the end of 2022.

5 Questions with Nikki Marchan, MPH. Senior Specialist, Antimicrobial Resistance, Association of Public Health Laboratories

Published on : Published by : Andy Eckert

Nikki Marchan is public health professional who is passionate about progressing the study of infectious diseases for enhanced prevention, detection, and response. As a Senior Specialist with the Association of Public Health Laboratories, she provides support for laboratory and surveillance activities and works on behalf of and in collaboration with public health laboratories, federal partners, and other public health organizations.

Gaithersburg’s VLP Therapeutics raises $16M Series A for cancer treatment vaccine R&D

Published on : Published by : BioBuzz Media

VLP Therapeutics raises $16M Series A for cancer treatment vaccine R&D GAITHERSBURG, Md., March 15, 2021 /PRNewswire/ — US-based biotech company VLP Therapeutics, Inc. (VLPT) announced on March 15 that it has raised US$16 million in a [….]

Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico

Published on : Published by : BioBuzz Media

Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico PREVENT-19 enrolls 30,000 volunteers across 118 sites in the U.S. and Mexico GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE [….]

5 Questions with Kurt Elam, Senior Director, Sales & Marketing for LabOwl

Published on : Published by : Andy Eckert

Kurt Elam joined ACC/Lab Owl in 2017 with 20+ years of specialty biopharmaceutical experience, focused primarily on oncology, infectious disease, and critical care/ICU medicine. He has overseen and managed the successful launch of over 16 new FDA approved products/compounds or new indications, and worked to gain formulary approval in managed care organizations, thereby improving access for patients.